Bismarck News Updates

The Cardiotoxicity market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players

 Breaking News
  • No posts were found

The Cardiotoxicity market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players

May 27
19:58 2021
The Cardiotoxicity market outlook is expected to change positively in the upcoming years because of increased global healthcare spending, improved awareness, and the proliferation of major players

Cardiotoxicity Market
As people have become more aware of this unique condition, medicines that account for the cardiotoxic consequences have been created. These factors, together with the expected launch of innovative therapies in the Cardiotoxicity market, would drive demand in the projected period (2021–2030).

The Cardiotoxicity Market Report by DelveInsight provides a detailed understanding of Cardiotoxicity, historical and forecasted epidemiology, and Cardiotoxicity market trends in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).

Some Key Highlights from the Cardiotoxicity Market Report

  • Cardiotoxicity was found in 39.6% of anthracycline-treated patients in a recent study (Sendon et al., 2020).

  • Cardiotoxicity also seen in patients who were taking anti-HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%). (Sendon et al., 2020).

  • Around one-third of cancer patients who receive chemotherapy drugs including trastuzumab (Herceptin) and anthracyclines have heart cell damage (University of Michigan, n.d.).

  • Cardiotoxicity pipeline therapies include Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), and others.

  • Moleculin Biotech, Monopar Therapeutics, among others are the major pharmaceutical companies in the Cardiotoxicity market.

To gain more insights request sample @ Cardiotoxicity Market Insights Report

Cardiotoxicity report includes the current clinical practises, new drugs, Cardiotoxicity market share of individual therapies, current and forecasted Cardiotoxicity market size from 2018 to 2030 segmented by seven major markets.

Cardiotoxicity: Disease Overview

Cardiotoxicity occurs when the heart muscle is damaged. Chemotherapy drugs or treatments for other diseases may cause Cardiotoxicity. As a result Cardiotoxicity causes the heart to weaken and become unable to pump blood across the body.

Several cancer drugs and therapies will damage the heart directly. Heart failure, high blood pressure, low blood pressure, heart attacks, rapid heartbeat, slow heart rate, or fluid around the heart are all possible side effects of these medications.

Cardiotoxicity Epidemiology Segmentation

  • Various Cancer Total Incident Cases

  • Various Cancer Total Number of Patients taking Chemotherapy

  • Cardiotoxicity Total Number of Patients taking Specific Chemotherapy Agents

  • Cardiotoxicity Total Number of Patients

Cardiotoxicity Treatment Landscape

The doctor may recommend reducing the dosage of the medication that caused the heart damage, stopping the medication, or switching to a different regimen, depending on the severity of the Cardiotoxicity and the patient’s overall health status. Cardiotoxicity can be treated with a variety of drugs, including:

  • Dexrazoxan

  • ACE inhibitors

  • Beta-blockers

  • Diuretics

  • Digoxin

  • Vasodilators

Cardiotoxicity Market

As people have become more conscious of this unusual symptom, medications have been developed that take into account the cardiotoxic effects. These factors will fuel the demand in the forecast period (2021–2030), along with the planned launch of emerging therapies such as Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), others in the Cardiotoxicity market.

Get more information @ Cardiotoxicity Market and Treatment Landscape

Cardiotoxicity Pipeline Therapies and Key Companies

  • Annamycin: Moleculin Biotech

  • Camsirubicin: Monopar Therapeutics

Table of Contents

1.

Report Introduction

2.

Executive Summary of Cardiotoxicity

3.

Cardiotoxicity Market Overview at a Glance

4.

Disease Background and Overview: Cardiotoxicity

5.

Case Reports of Cardiotoxicity

6.

Cardiotoxicity Patient Journey

7.

Cardiotoxicity Epidemiology and Patient Population

8.

Epidemiology of Cardiotoxicity by Countries (2018–2030)

9.

Cardiotoxicity Treatments and Medical Practices

10.

Cardiotoxicity Marketed Therapies

11.

Cardiotoxicity Emerging Therapies 

12.

Cardiotoxicity Market Size

13.

7MM: Country-wise Market Analysis

14.

Cardiotoxicity Market Drivers

15.

Cardiotoxicity Market Barriers

16.

SWOT Analysis

17.

KOL Views

18.

Reimbursement and market access

19.

Report Methodology

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Dilated Cardiomyopathy Market 

Get comprehensive historical and forecast analysis of Dilated Cardiomyopathy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Amgen, Pfizer, Vericel, Berlin Cures GmbH, MyoKardia, Cumberland Pharmaceuticals, Capricor Therapeutics, among others. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Categories